Compare Costco Wholesale Corporation (COST) vs Pfizer Inc (PFE) Price & Performance

COST trades at $926.43, up 1.11% today, with a bearish technical signal but strong fundamentals. Revenue grew to $275.24B in 2025, with net income up to $8.10B, and March 2026 sales surged 11.3% year-over-year (Costco report, April 8, 2026). Valuation ratios are elevated, with a P/E of 46.6, while analyst consensus is bullish with a $1,120 price target. Recent membership fee hikes and institutional buying support growth prospects.

Outlook remains positive due to steady revenue growth and high membership renewal rates, but risks include rich valuations and competitive pressures. The stock offers long-term value if pullbacks occur, with earnings momentum key for upside. Bearish technicals suggest near-term caution, though fundamentals underpin investor confidence.

Pfizer (PFE) trades at $24.25, up 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.75, beating expectations, and maintains a dividend of $0.43 per share. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, with key catalysts expected in 2026. Financials show revenue of $62.58B in 2025, with a net income margin of 11.83% and a P/E ratio of 18.69.

The outlook for Pfizer is mixed, with analyst consensus leaning toward Hold (58.98%) but a price target of $28.78 suggesting potential upside. Investment opportunities include a strong dividend yield and pipeline advancements, while risks involve patent cliffs and competitive pressures. The stock's current valuation appears reasonable, but execution on pipeline developments is critical for future growth.